Prevention of stroke and systemic embolization in atrial fibrillation: a Canadian perspective

Area of Science:

• Cardiology and Neurology
• Pharmacology and Therapeutics

Background:

• Atrial fibrillation (AF) affects approximately 1% of the general population, with higher prevalence in elderly individuals.
• AF significantly elevates stroke risk, ranging from under 1% to 20% annually based on risk factors, compared to 4.5% without treatment.
• Traditional antithrombotic therapies, including vitamin K antagonists (VKAs) and aspirin, reduce stroke risk but carry bleeding risks.

Purpose of the Study:

• To evaluate the efficacy and safety of new oral anticoagulants (NOACs) for stroke prevention in patients with atrial fibrillation.
• To compare the performance of NOACs (dabigatran, rivaroxaban, apixaban) against traditional VKAs, specifically warfarin.

Main Methods:

• Analysis of large-scale randomized clinical trials comparing NOACs with warfarin.
• Assessment of stroke risk reduction and major hemorrhage events associated with different anticoagulant therapies.

Main Results:

• NOACs demonstrated significant advantages in both efficacy and safety compared to VKAs in large clinical trials.
• While specific benefits vary among dabigatran, rivaroxaban, and apixaban, all offer excellent stroke prevention alternatives.
• The risk reduction for stroke generally outweighs the risks of major hemorrhage associated with oral anticoagulation.

Conclusions:

• New oral anticoagulants represent a superior alternative to VKAs for stroke prevention in atrial fibrillation patients.
• Recent clinical practice guidelines endorse NOACs as recommended alternatives to VKAs, reflecting their improved profile.